BUSINESS
Government’s free vaccination drive kills market for private hospitals, 25% allocation largely unutilised
With the wider availability of vaccines, people prefer to get their jabs at government centres rather than pay for shots at private hospitals.
BUSINESS
Healthtech platform Medikabazaar raises $75 million from Creagis, CDC Group
The current investment will be utilized to strengthen Medikabazaar’s digital capabilities, deepen the supply ecosystem, technology driven distribution channels and bolster capacity to provide a wider range of leading-edge quality medical supplies across diverse geographical regions.
BUSINESS
J&J says launch date of COVID-19 shots in India not decided, still in talks with govt
COVID-19 vaccines would be on the agenda of the Quad meeting scheduled on September 24 between the heads of the governments of the US, India, Japan and Australia, sources told Moneycontrol
BUSINESS
Industry says UK’s non-recognition of Indian vaccine certificates ‘unfair’
India is the leading vaccine manufacturer for the world. Not recognising India's vaccine certificate is not acceptable, Dr Alok Roy, Chair of FICCI Health Services Committee, said. India’s digital certification is far more reliable than other countries’ manual systems, tweeted Kiran Mazumdar-Shaw, Chairperson of Biocon.
BUSINESS
MSF asks Regeneron to make COVID antibody cocktail affordable; forego patent claims
Regenron has priced the antiviral cocktail at $820 (Rs 59,750) in India, $2,000 in Germany and $2,100 in the US. It has also filed patent applications in at least 11 low= and middle-income countries
BUSINESS
Aurobindo Pharma's subsidiary seeks marketing approval of its first biosimilar product from EMA
Aurobindo Pharma is developing biosimilars for global markets through its subsidiary CuraTeQ Biologics with focus on oncology and immunology segments.
BUSINESS
Lupin's Goa plant: USFDA finds certain investigation, material testing deficiencies
Lupin said the company is confident of addressing the observations satisfactorily
BUSINESS
WHO panel to review Covaxin data for emergency-use listing on October 5
Inclusion of indigenously developed Covaxin in the WHO list will boost global acceptance of the Covid-19 vaccine.
WORLD
UK to allow entry to travellers vaccinated with Covishield from October 4
Indians will still have to take tests on arrival and quarantine for ten days.
BUSINESS
Explainer: Why India is relaxing export restrictions on COVID-19 vaccines
For one, India has to keep its commitment under a global initiative called COVAX. The other reason, as an expert says, is that if India doesn't ease export restrictions, it will benefit China, which is making deeper inroads into low and middle-income countries with vaccine diplomacy.
BUSINESS
UK may review its new COVID travel policy for India: Sources
"Everybody knows that it is identical, it is been proven. We have submitted the data to EMA and the UK MHRA. They are reviewing it, I have had a personal consultation with the regulator there, they are going to get back to us shortly," said Adar Poonawalla, CEO of SII.
BUSINESS
India to resume exports of surplus COVID-19 vaccines from October under Vaccine Maitri programme
Union health minister Mansukh Mandaviya said more than 30 crore doses will be produced in October and more than 100 crores in the coming quarter.
BUSINESS
Adar Poonawalla-backed Mylab acquires point-of-care testing provider Sanskritech
Sanskritech's Swayam is a portable diagnostic and telemedicine point-of-care system that can be used to create a small lab anywhere. This will allow people to test for a wide range of diseases within a few minutes
BUSINESS
Biocon, SII deal to extend to exploring partnership in biologics, mRNA vaccines
Biocon and SII are exploring development and commercialisation of SII's biologic portfolio, considering manufacture of raw materials for vaccines and biologics, and plan to develop and make drugs and vaccines based on mRNA platform.
BUSINESS
Sputnik Light single-dose vaccine launch in India may get delayed
An expert panel of the Central Drugs Standard Control Organisation asks company to conduct Phase-3 immune-bridging clinical trials on Indian population. Dr Reddy's spokesperson declines to say when the trial will start.
BUSINESS
Delayed launch of Glumetza: Lupin settles case for $248 million
The law suits in US courts alleged that the 2012 settlement of patent litigation regarding Glumetza delayed the availability of generic alternatives, causing consumers to pay higher prices for the drug.
BUSINESS
DCGI led panel formed to frame new New Drugs, Cosmetics and Medical Devices Bill starts process
"The committee has decided to conduct a consultative meeting with the Consumer Associations scheduled to held on September 19 between 2 - 4 pm," the notification released by Somani said.
BUSINESS
No new side effects found in COVID-19 antiviral Favipiravir: Glenmark
Glenmark said the time for fever resolution was four days while time for clinical cure was seven days.
BUSINESS
Poonawalla-backed Wellness Forever to file for Rs 1,600-crore IPO
The retail pharmacy chain will file its draft documents by end-September.
BUSINESS
Laurus Labs joins hands with Unitaid, CHAI to develop and commercialise pediatric HIV drug combo
Laurus will be provided with a financial incentive for a portion of their development and commercialisation costs. CHAI will work closely with Laurus Labs to provide technical and regulatory support to enable accelerated generic development and regulatory submission of the medication.
BUSINESS
IPO-bound PharmEasy parent appoints five independent directors, to hire over 200 engineers
“The fresh appointments bring a great amount of cognitive diversity to the board, with luminaries from the world of public service, technology, pharma, medical fraternity, and the consumer sector," the company said in a statement.
BUSINESS
Advanced Enzymes says its enzymes, probiotics aid faster recovery in long-COVID patients
The products were launched on Amazon under brand names ‘ImmunoSEB’ and ‘Biome ULTRA’ in the US and Indian markets.
BUSINESS
NABL a voluntary accreditation body, has no regulatory powers: N Venkateswaran, CEO
"Checking of compliance to the regulatory requirements falls under the purview of the respective applicable regulator," Venkateswaran says. NABL has been drawing flak, especially for issuing accreditation for labs that are not complying with regulatory practices.
BUSINESS
Indian pharmaceutical market grow at 17.7% in August
India’s $1.8 trillion pharmaceuticals market is showing signs of returning to normalcy as sales of Non-COVID products, which account for 63 percent of the market, is rising strongly while growth of some pandemic-related products like vitamins has tapered.
